Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYX-2925 in Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT03219320Phase 2Completed
- Sponsor
- Aptinyx Inc.
- Start
- Jun 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NYX-2925 in diabetic peripheral neuropathy (DPN), sponsored by Aptinyx Inc.. Started Jun 2017; status: completed.
02
Drugs
NYX-2925
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT03219320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219320.